评价表柔比星联合紫杉醇在三阴性乳腺癌中的临床应用价值  

Evaluation of Clinical Application Value of Combined Paclitaxel and Paclitaxel in Three Negative Breast Cancer

作　　者：胡春霞[1] 

机构地区：[1]连云港市第二人民医院肿瘤科,江苏连云港222006

出　　处：《中国继续医学教育》2016年第30期134-135,共2页China Continuing Medical Education

摘　　要：目的评价表柔比星联合紫杉醇在三阴性乳腺癌的临床应用价值。方法选取在我院治疗的54例局部晚期三阴性乳腺癌患者作为研究对象,对其随机分组。对照组采用表柔比星单药治疗,实验组采用表柔比星联合紫杉醇治疗,比较两组患者的临床疗效及不良反应发生率。结果实验组患者的治疗有效率为62.96%,高于对照组,P<0.05,但两组之间的不良反应发生情况差异无统计学意义,P>0.05。结论表柔比星联合紫杉醇在三阴性乳腺癌治疗中具有较显著的临床疗效。Objective To analyze the clinical effect of the combination of epirubicin and paclitaxel in the treatment of three negative breastcancer. Methods 54 cases of three negative breast cancer patients treated in our hospital were selected as the target, random grouping of the implementation. The control group was treated with the epirubicin, the experimental group was treated with the combination of the epirubicin and paclitaxel, compared with the two groups of patients with clinical efficacy and adverse reaction rate. Results The effective rate of the experimental group was 62.96%, which was significantly higher than that of the control group, P〈0.05, but there was no significant difference in the incidence of adverse reactions between the two groups, P〈0.05. Conclusion The combination of epirubicin and paclitaxel in the treatment of three negative breast cancer has a significant clinical effect.

关 键 词：表柔比星 紫杉醇 三阴性乳腺癌 

分 类 号：R737[医药卫生—肿瘤]